Flatiron Health’s research at ASH 2023 includes presentations on innovative health equity cancer research and the impact of machine learning in studying rare diseases, particularly in hematologic malignancies.
Prior to the conference, Flatiron experts engaged in a panel discussion on these key topics, highlighting the role and impact of evidence solutions across the hematologic drug development lifecycle. In this webinar, you’ll hear our panelists discuss:
-
Challenges and trends in hematologic drug development, research, and evidence generation and resulting impact on patient care and outcomes
-
Perspectives on the FDA’s guidance on diversity plans for clinical trials and how fit-for-purpose evidence solutions can better equip biopharma to fulfill this mandate
-
The role of AI methodologies, including machine learning and natural language processing, in scaling evidence generation and insights for hematologic drug development
Speakers:
-
Jenna Collins, MPH, Director, Scientific Engagement (Moderator)
-
Amy Pierre, MSN, RN, ANP-BC, Senior Clinical Director
-
Cleo A. Ryals, PhD, Senior Director, Head of Health Equity
-
Aaron Cohen, MD, MSCE, Medical Director
Visit us at booth #3156 and learn more about our research presence.
